Corbin Capital Partners L.P. Lowers Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Corbin Capital Partners L.P. decreased its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 20.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 682,487 shares of the biopharmaceutical company's stock after selling 170,817 shares during the period. Arbutus Biopharma comprises 3.7% of Corbin Capital Partners L.P.'s portfolio, making the stock its 5th biggest position. Corbin Capital Partners L.P. owned about 0.36% of Arbutus Biopharma worth $2,232,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. bought a new position in shares of Arbutus Biopharma in the 4th quarter valued at about $34,000. Xponance Inc. acquired a new position in Arbutus Biopharma during the fourth quarter valued at approximately $34,000. Raymond James Financial Inc. bought a new position in Arbutus Biopharma in the fourth quarter valued at approximately $34,000. Cibc World Markets Corp acquired a new position in shares of Arbutus Biopharma during the 4th quarter worth approximately $45,000. Finally, XTX Topco Ltd raised its stake in shares of Arbutus Biopharma by 76.2% during the 3rd quarter. XTX Topco Ltd now owns 30,013 shares of the biopharmaceutical company's stock worth $116,000 after purchasing an additional 12,975 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Tuesday, January 21st. StockNews.com lowered shares of Arbutus Biopharma from a "hold" rating to a "sell" rating in a research note on Thursday, March 13th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $5.50.

Remove Ads

Arbutus Biopharma Stock Down 0.6 %

Shares of ABUS stock traded down $0.02 during trading on Tuesday, reaching $3.37. 680,693 shares of the company's stock were exchanged, compared to its average volume of 1,029,364. Arbutus Biopharma Co. has a twelve month low of $2.30 and a twelve month high of $4.73. The firm's fifty day moving average price is $3.32 and its 200-day moving average price is $3.59. The stock has a market capitalization of $638.59 million, a PE ratio of -7.84 and a beta of 1.93.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.